Tallac Therapeutics, Inc.
BURLINGAME, CA · Founded 2018 · CIK 0001819027 · Biotech · Private
Toll-like Receptor Agonist Antibody Conjugates (TRAAC) – oligonucleotide-based antibody drug conjugates delivering TLR9 agonists to tumors
tallactherapeutics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $21M
- 1 Form D · Jul 2020
- 74 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 32
- 3 granted · 29 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $21,175,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2337 | 3P BIOTECHNOLOGIES, INC. | — | — |
| 2338 | Mythic Therapeutics | — | $53M |
| 2339 | DEEPSEQAI LLC | — | — |
| 2340 | Tallac Therapeutics, Inc. | — | $21M |
| 2341 | AION Healthspan, Inc. | — | $2.9M |
| 2342 | Avm Biotechnology, LLC | — | $5.8M |
| 2343 | INFIXION BIOSCIENCE, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Christine BrennanDirector
- Michael CarusiDirector
- Isaac ChengDirector
- Ran GengDirector
- Corey GoodmanDirector
- Jaume PonsDirector
- Hong WanDirector · Executive Officer
Patents
- Methods Of Treating Cancer Using ANTI-CD22 Antibody Oligonucleotide Conjugatesapplication
- Methods Of Treating Cancer Using ANTI-CD22 Antibody Oligonucleotide Conjugatesapplication
- Immunomodulating Polynucleotides, Antibody Conjugates Thereof, And Methods Of Their Usegranted
- Sirp-alpha Antibodies And Conjugatesapplication
- Transglutaminase-mediated Conjugationapplication
- Transglutaminase-mediated Conjugationapplication
- Transglutaminase-mediated Conjugationgranted
- Transglutaminase-mediated Conjugationapplication
- Transglutaminase-mediated Conjugationgranted
- Immunomodulating Polynucleotide Conjugates And Methods Of Useapplication
- Use Of Immunomodulating Targeted Polynucleotide Conjugates For Use With Immune Honing Agentapplication
- Methods Of Treating Cancer Using ANTI-CD22 Antibody Oligonucleotide Conjugatesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.